Biotech's Freer Hand to Fight Terror

The FDA is relaxing some testing procedures, including those involving animals, to speed research. The goal: More vaccines sooner

With the severe acute respiratory syndrome (SARS) epidemic spreading, it's easy to overlook an equally serious threat: bioterrorism. The situation in Iraq and heightened tension throughout the Middle East may raise the likelihood of a chemical or biological attack against U.S. targets. The Homeland Security Dept. has repeatedly warned that terrorist groups could be planning such assaults (see BW Online, 4/28/03, "'Security Becomes Embedded'"). And as the still-unsolved anthrax attacks of 2001 showed, America's arsenal of vaccines and drugs is far from adequate.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.